HK Stock Market Move | SIHUAN PHARM (00460) further rises by over 9% and institutions are optimistic about its dual drivers in medical aesthetics and innovative drugs, which will further accelerate growth.

SIHUAN PHARM(00460) rose by over 9%, rising by 8.9% to HK$1.59 as of the time of writing, with a turnover of HK$150 million. On the news front, recently, SIHUAN PHARM announced that six new specifications of the self-developed polylactic acid facial filler (market abbreviation "Youthful injection") by Meiyankongjian Biological Technology (Jilin) Co., Ltd., a subsidiary of the Group, have officially been approved by the China National Medical Products Administration. The founder previously pointed out that the breakthrough in the company's medical beauty pipeline and cooperation, the release of innovative drug value, and the dual drive will further accelerate. The bank pointed out that the current pipeline matrix is accelerating the volume: botulinum toxin continues to steadily realize high growth, new products such as Youthful injection and Girl injection are starting to volume up, and the new product momentum Suhuiguang is expected to become an additional growth pole; follow-up pipelines such as regenerative, collagen, optoelectronic equipment, weight loss products are expected to continue to land and realize, providing sufficient long-term momentum. In addition, the recent outbreak of the Nipah virus in India has attracted attention. In 2020, SIHUAN PHARM announced a cooperation framework agreement in the pharmaceutical field with Indian registered company India Hedern Pharmaceuticals Limited (Hedern). According to the cooperation framework agreement, the cooperation includes close cooperation and common development in the research and development of drugs in the cardiovascular, central nervous system, and anti-infection fields including novel coronavirus (2019-nCoV), product registration, technology transfer, raw material supply, localization production, and sales.